Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Notes Payables (2019 - 2020)

Protalix BioTherapeutics (PLX) has 2 years of Notes Payables data on record, last reported at $4.1 million in Q4 2020.

  • For Q4 2020, Notes Payables fell 5.0% year-over-year to $4.1 million; the TTM value through Dec 2020 reached $4.1 million, down 5.0%, while the annual FY2020 figure was $4.1 million, 5.0% down from the prior year.
  • Notes Payables reached $4.1 million in Q4 2020 per PLX's latest filing, down from $4.3 million in the prior quarter.
  • Across five years, Notes Payables topped out at $4.3 million in Q4 2019 and bottomed at $4.1 million in Q4 2020.